Physician profile
Jensen Galetta
NPI 1902414246
$5,231.05
in general payments reported to CMS, 2019-2025
40 companies · $3,381 in 2025
The $3,381 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $241 · 2023: $279 · 2024: $1,149 · 2025: $3,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,776 · Education: $32.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.43 |
| Education | $32.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $591.25 | 2023-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.93 | 2024-2025 | Ofev, Jascayd |
| Genzyme Corporation | $390.32 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $310.34 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Jazz Pharmaceuticals INC. | $296.70 | 2024-2025 | |
| Glaxosmithkline, LLC. | $267.54 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Ani Pharmaceuticals, INC. | $240.69 | 2024-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $233.39 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $181.69 | 2025 | Ohtuvayre |
| Medtronic, INC. | $178.62 | 2022-2023 | Intellis Adaptivestim |
| Insmed, INC. | $177.76 | 2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $177.29 | 2024-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $166.92 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $158.10 | 2025 | Acthar |
| Harmony Biosciences LLC | $137.23 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.00 | 2021 | |
| Intuitive Surgical, INC. | $117.97 | 2025 | |
| Mylan Specialty L.P. | $113.15 | 2024 | Yupelri |
| Lilly USA, LLC | $105.54 | 2025 | Zepbound |
| Si-Bone, INC. | $89.39 | 2022-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $89.38 | 2025 | Lumryz |
| United Therapeutics Corporation | $82.80 | 2024-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $49.22 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Silk Road Medical, INC. | $46.24 | 2021-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Axsome Therapeutics, INC. | $45.12 | 2025 | Sunosi |
| Electromed, INC. | $44.32 | 2025 | Smartvest |
| Kci USA, INC. | $39.42 | 2023 | Prevena |
| Depuy Synthes Sales INC. | $39.14 | 2023 | Synthecel, Matrixneuro |
| Merck Sharp & Dohme LLC | $29.88 | 2024 | Keytruda |
| Boston Scientific Corporation | $29.27 | 2021 | |
| Amneal Pharmaceuticals LLC | $27.96 | 2023 | Lioresal (Baclofen) |
| Liquidia Technologies, INC. | $22.50 | 2025 | Yutrepia |
| Microtransponder, INC. | $21.64 | 2023 | |
| Vifor Pharma, INC. | $21.02 | 2025 | Zemaira |
| Inogen, INC. | $20.76 | 2025 | |
| Orthofix Medical, INC. | $20.75 | 2022 | |
| Amgen INC. | $19.17 | 2025 | Tezspire |
| Alexion Pharmaceuticals, INC. | $16.79 | 2022 | |
| Arteriocyte Medical Systems, INC. | $13.34 | 2023 | Magellan |
| Abbvie INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jensen Galetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.